Analgesia and haloperidol: a hypothesis.
We have previously reported 10 patient histories involving various intractable pain syndromes where the administration of Haloperidol either eliminated the need for narcotic analgesics or resulted in a significant reduction in narcotic dosage. We are presently undertaking a controlled double-blind evaluation of Haloperidol as an adjunctive treatment for intractable cancer pain. Based upon the reported clinical observations, these findings are discussed from the following aspects: 1. The isomeric similarity of Haloperidol to Meperidine. 2. Dose response between Haloperidol and analgesic effect. 3. The clinical literature regarding the use of Haloperidol for the effective withdrawal or maintenance of narcotic addicts. 4. The analgesic property as it relates to the opiate receptor.
D000700:Analgesics / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006556:Heroin Dependence / Q000188:drug therapy; D006801:Humans; D008614:Meperidine; D010148:Intractable Pain / Q000188:drug therapy*; D011957:Receptors, Opioid / Q000187:drug effects
D000700:Analgesics; D011957:Receptors, Opioid; D008614:Meperidine; D006220:Haloperidol